Saxenda

Phase 2Small molecule

Novo Nordisk

Saxenda is one of 86 small molecule programs targeting Weight loss. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Weight LossActive, not recruiting

Hypothalamic ObesityActive, not recruiting

ObesityActive, not recruiting

Weight LossPreclinical

Active, not recruiting

Hypothalamic ObesityPhase 1

Active, not recruiting

ObesityPhase 2

Active, not recruiting

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

Saxenda

Novo Nordisk

Phase 2

2 2

Amidate

Pfizer

Preclinical

—3

Calciferol

Alnylam Pharmaceuticals

Adenocard

Activella

Colcrys

Alnylam Pharmaceuticals

Preclinical

—7

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 8

Cetrotide

EMD Serono

Preclinical

2 9

Spiriva

Boehringer Ingelheim

Preclinical

1 10

Flagyl

DDePuy Orthopaedics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Weight loss2 trials

To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

Completed·TTexas Tech University·N/A·NCT03795701·73 enrolled

A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

Completed· Novo Nordisk logo

Novo Nordisk··NCT05153590·269 enrolled

Obesity2 trials

Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity

Completed·SSciwind Biosciences APAC CO Pty. Ltd.·Phase 2·NCT05111912·206 enrolled

Saxenda in Obesity Services (STRIVE Study)

Completed·UUniversity of Leicester·Phase 4·NCT03036800·392 enrolled

Overweight2 trials

3mg Liraglutide for Overweight or Obesity

Completed·UUniversity Hospitals Coventry and Warwickshire NHS Trust··NCT03885297·43 enrolled

A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT04903509·95 enrolled

Hypothalamic Obesity1 trial

The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study

Unknown status·SSeoul National University Hospital·Phase 1·NCT06217848·50 enrolled

Gastrectomy1 trial

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

Completed·MMayo Clinic·Phase 3·NCT03115424·46 enrolled

1 more indication

Clinical Efficacy and Safety1 trial

Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery

Completed·NNYU Langone Health·Phase 4·NCT03048578·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Saxenda. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Saxenda compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Saxenda. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novo Nordisk

Saxenda

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Weight loss2 trials

Obesity2 trials

Overweight2 trials

Hypothalamic Obesity1 trial

Gastrectomy1 trial

Clinical Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News